A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo

BACKGROUND: We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS: Patients were randomly assigned in a 1:1:1:1 ratio to one of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Makoto, Li, Chung Pin, Ikeda, Masafumi, Ishii, Hiroshi, Mizuno, Nobumasa, Yamaguchi, Taketo, Ioka, Tatsuya, Oh, Do Youn, Ichikawa, Wataru, Okusaka, Takuji, Matsuyama, Yutaka, Arai, Daichi, Chen, Li Tzong, Park, Young Suk, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532401/
https://www.ncbi.nlm.nih.gov/pubmed/28634650
http://dx.doi.org/10.1007/s00280-017-3351-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532401/
https://www.ncbi.nlm.nih.gov/pubmed/28634650
http://dx.doi.org/10.1007/s00280-017-3351-4

Ejemplares similares